The variant itself does not seem to be the single driver mutation in cancer, but as KMT2D variants are recurrently acquired in cancer, the loss of KMT2D pronounced tumor progression, or as observed here, therapy resistance potentially due to increased genetic instability and epigenetic reprogramming. Here, KMT2D is linked to neoplasm.